BRAF positive

Genetic test showed a positive BRAF V600E gene mutation. Treatment with dabrafenib and trametinib was initiated nine days after lenvatinib was discontinued.

MWA achieved effective local control with low complication rates in T1N0M0 PTC regardless of BRAF V600E mutation status.

It was determined that that the positivity of BRAF, TERT, and both mutations was associated with large tumor size, and the extra thyroidal spread was higher in BRAF positivity, but there was no statistically significant difference in metastasis, recurrence, and survival. The presence of BRAF and TERT mutations should be evaluated with more comprehensive studies in terms of clinical benefit prior to their routine use in our country.

The patient was initiated on ipilimumab and nivolumab immunotherapy, which was well tolerated with a favourable response. This case illustrates the critical role of PET-CT in distinguishing tumour thrombus from embolic disease and demonstrates the value of EBUS as a minimally invasive, safe, and effective diagnostic tool in high-risk settings. It also highlights how perseverance in diagnostic efforts can facilitate early treatment, even in complex and high-risk scenarios.

The study showed an even distribution of colorectal adenocarcinoma incidence between males and females, with the highest rates of diagnosis in patients aged more than 50 years. Patients with stage III and IV disease had a higher rate of serum CEA elevation as compared to stage I and II.

P2, N=186, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended

The next-generation sequencing performed on skin and bone marrow biopsies showed identical mutations in ASXL1, CALR, and TET2 genes, while the LCS tumor showed an additional BRAF mutation. This case presents the case of progression of MPN to LCS supported by molecular evidence.

The youngest BRAF-positive dogs of these predisposed breeds (n = 4) were 5 years old. In conclusion, screening tests in predisposed breeds may be recommended from the age of 5 years.

A surgical approach, while varying with the surgeon's skills, represents a mandatory step to ensure a better prognosis. In addition to a meticulous histological characterization, genetic/molecular features provide valuable information regarding the outcome and can further help with the decision to use new anti-cancer drugs if tumor response upon radioiodine therapy is no longer achieved; such a development is expected in this disease stage in association with a BRAF-positive configuration.

Ameloblastoma with BRAF V600E mutation has been observed with a higher recurrence rate and an increased initial volume of the lesion. The results obtained demonstrate an increased aggressiveness and invasiveness of BRAF + ameloblastomas.

This included a combination of tislelizumab immunotherapy, chemotherapy, and anlotinib targeted therapy, which significantly reduced the size of tumor. The present case demonstrates the potential of a multimodal treatment regimen encompassing chemotherapy, immunotherapy and targeted therapy, followed by surgical excision, for primary thyroid squamous cell carcinoma. Further studies are needed to validate the efficacy and safety of this combined treatment modality in larger patient populations.

P4, N=5, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine